{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:49:13Z","timestamp":1787017753550,"version":"build-2736575974"},"reference-count":59,"publisher":"American Association for Cancer Research (AACR)","issue":"11","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Breast cancer metastasis to the bone occurs frequently, causing numerous complications including severe pain, fracture, hypercalcemia, and paralysis. Despite its prevalence and severity, few effective therapies exist. To address this, we examined whether the heat shock protein 90 (Hsp90) inhibitor, 17-allylamino-17-demethoxygeldanamycin (17-AAG), would be efficacious in inhibiting breast cancer metastasis to bone. Utilizing the human breast cancer subline, MDA-MB-231SA, previously in vivo selected for its enhanced ability to generate osteolytic bone lesions, we determined that 17-AAG potently inhibited its in vitro proliferation and migration. Moreover, 17-AAG significantly reduced MDA-MB-231SA tumor growth in the mammary-fat pad of nude mice. Despite these findings, 17-AAG enhanced the incidence of bone metastasis and osteolytic lesions following intracardiac inoculation in the nude mouse. Consistent with these findings, 17-AAG enhanced osteoclast formation 2- to 4-fold in mouse bone marrow\/osteoblast cocultures, receptor activator of nuclear factor \u03baB ligand (RANKL)\u2013stimulated bone marrow, and RAW264.7 cell models of in vitro osteoclastogenesis. Moreover, the drug enhanced osteoclastogenesis in human cord blood progenitor cells, demonstrating that its effects were not limited to mouse models. In addition to 17-AAG, other Hsp90 inhibitors, such as radicicol and herbimycin A, also enhanced osteoclastogenesis. A pro-osteolytic action of 17-AAG independent of tumor presence was also determined in vivo, in which 17-AAG\u2013treated tumor-nai\u0308ve mice had reduced trabecular bone volume with an associated increase in osteoclast number. Thus, HSP90 inhibitors can stimulate osteoclast formation, which may underlie the increased incidence of osteolysis and skeletal tumor incidence caused by 17-AAG in vivo. These data suggest an important contraindication to the Hsp90 targeted cancer therapy currently undergoing clinical trial.<\/jats:p>","DOI":"10.1158\/0008-5472.can-04-4458","type":"journal-article","created":{"date-parts":[[2005,9,15]],"date-time":"2005-09-15T17:47:30Z","timestamp":1126806450000},"page":"4929-4938","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["The Heat Shock Protein 90 Inhibitor, 17-Allylamino-17-demethoxygeldanamycin, Enhances Osteoclast Formation and Potentiates Bone Metastasis of a Human Breast Cancer Cell Line"],"prefix":"10.1158","volume":"65","author":[{"given":"John T.","family":"Price","sequence":"first","affiliation":[{"name":"1Tumour Cell Migration and Metastasis Laboratory,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian M.W.","family":"Quinn","sequence":"additional","affiliation":[{"name":"2Bone Joint and Cancer Laboratory,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie A.","family":"Sims","sequence":"additional","affiliation":[{"name":"2Bone Joint and Cancer Laboratory,"},{"name":"5Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Vieusseux","sequence":"additional","affiliation":[{"name":"1Tumour Cell Migration and Metastasis Laboratory,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Waldeck","sequence":"additional","affiliation":[{"name":"1Tumour Cell Migration and Metastasis Laboratory,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Docherty","sequence":"additional","affiliation":[{"name":"1Tumour Cell Migration and Metastasis Laboratory,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Myers","sequence":"additional","affiliation":[{"name":"6Physiology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nakamura","sequence":"additional","affiliation":[{"name":"2Bone Joint and Cancer Laboratory,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Waltham","sequence":"additional","affiliation":[{"name":"3Pharmacogenomics Laboratory, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Gillespie","sequence":"additional","affiliation":[{"name":"2Bone Joint and Cancer Laboratory,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik W.","family":"Thompson","sequence":"additional","affiliation":[{"name":"4Victorian Breast Cancer Research Consortium Invasion and Metastasis Laboratory, St. Vincent's Institute; and Departments of"},{"name":"7Surgery, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2005,6,1]]},"reference":[{"key":"2022061620110284900_B1","doi-asserted-by":"crossref","unstructured":"Price JT, Bonovich MT, Kohn EC. The biochemistry of cancer dissemination. Crit Rev Biochem Mol Biol\u20081997; 32: 175\u2013253.","DOI":"10.3109\/10409239709082573"},{"key":"2022061620110284900_B2","doi-asserted-by":"crossref","unstructured":"Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer\u20081997; 80: 1529\u201337.","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F"},{"key":"2022061620110284900_B3","doi-asserted-by":"crossref","unstructured":"Hart IR. \u201cSeed and soil\u201d revisited: mechanisms of site-specific metastasis. Cancer Metastasis Rev\u20081982; 1: 5\u201316.","DOI":"10.1007\/BF00049477"},{"key":"2022061620110284900_B4","doi-asserted-by":"crossref","unstructured":"Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer\u20082002; 2: 584\u201393.","DOI":"10.1038\/nrc867"},{"key":"2022061620110284900_B5","doi-asserted-by":"crossref","unstructured":"Boyce BF, Yoneda T, Guise TA. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer\u20081999; 6: 333\u201347.","DOI":"10.1677\/erc.0.0060333"},{"key":"2022061620110284900_B6","doi-asserted-by":"crossref","unstructured":"Coleman RE. Management of bone metastases. Oncologist\u20082000; 5: 463\u201370.","DOI":"10.1634\/theoncologist.5-6-463"},{"key":"2022061620110284900_B7","doi-asserted-by":"crossref","unstructured":"Roodman GD. Mechanisms of bone metastasis. N Engl J Med\u20082004; 350: 1655\u201364.","DOI":"10.1056\/NEJMra030831"},{"key":"2022061620110284900_B8","doi-asserted-by":"crossref","unstructured":"Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature\u20082001; 411: 375\u20139.","DOI":"10.1038\/35077241"},{"key":"2022061620110284900_B9","doi-asserted-by":"crossref","unstructured":"Chung LW. Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. Cancer\u20082003; 97: 772\u20138.","DOI":"10.1002\/cncr.11140"},{"key":"2022061620110284900_B10","doi-asserted-by":"crossref","unstructured":"O'Keefe RJ, Guise TA. Molecular mechanisms of bone metastasis and therapeutic implications. Clin Orthop 2003;S100\u20134.","DOI":"10.1097\/01.blo.0000093847.72468.2f"},{"key":"2022061620110284900_B11","doi-asserted-by":"crossref","unstructured":"Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol\u20082000; 18: 1378\u201391.","DOI":"10.1200\/JCO.2000.18.6.1378"},{"key":"2022061620110284900_B12","doi-asserted-by":"crossref","unstructured":"Diel IJ. Antitumour effects of bisphosphonates: first evidence and possible mechanisms. Drugs\u20082000; 59: 391\u20139.","DOI":"10.2165\/00003495-200059030-00001"},{"key":"2022061620110284900_B13","doi-asserted-by":"crossref","unstructured":"Young JC, Barral JM, Ulrich Hartl F. More than folding: localized functions of cytosolic chaperones. Trends Biochem Sci\u20082003; 28: 541\u20137.","DOI":"10.1016\/j.tibs.2003.08.009"},{"key":"2022061620110284900_B14","doi-asserted-by":"crossref","unstructured":"Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90\/hsp70-based chaperone machinery. Exp Biol Med (Maywood)\u20082003; 228: 111\u201333.","DOI":"10.1177\/153537020322800201"},{"key":"2022061620110284900_B15","doi-asserted-by":"crossref","unstructured":"Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol\u20082003; 15: 419\u201324.","DOI":"10.1097\/00001622-200311000-00003"},{"key":"2022061620110284900_B16","doi-asserted-by":"crossref","unstructured":"Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett\u20082004; 206: 149\u201357.","DOI":"10.1016\/j.canlet.2003.08.032"},{"key":"2022061620110284900_B17","doi-asserted-by":"crossref","unstructured":"Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell\u20082003; 3: 213\u20137.","DOI":"10.1016\/S1535-6108(03)00029-1"},{"key":"2022061620110284900_B18","doi-asserted-by":"crossref","unstructured":"Eustace BK, Sakurai T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for hsp90 \u03b1 in cancer cell invasiveness. Nat Cell Biol\u20082004; 6: 507\u201314.","DOI":"10.1038\/ncb1131"},{"key":"2022061620110284900_B19","unstructured":"Myoui A, Nishimura R, Williams PJ, et al. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res\u20082003; 63: 5028\u201333."},{"key":"2022061620110284900_B20","unstructured":"Weber KL, Doucet M, Price JE, Baker C, Kim SJ, Fidler IJ. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res\u20082003; 63: 2940\u20137."},{"key":"2022061620110284900_B21","doi-asserted-by":"crossref","unstructured":"Tester AM, Waltham M, Oh SJ, et al. Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. Cancer Res\u20082004; 64: 652\u20138.","DOI":"10.1158\/0008-5472.CAN-0384-2"},{"key":"2022061620110284900_B22","doi-asserted-by":"crossref","unstructured":"Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest\u20081997; 99: 2509\u201317.","DOI":"10.1172\/JCI119435"},{"key":"2022061620110284900_B23","unstructured":"Quinn JMW, Nakamura A, Docherty SE, et al. Inhibition of chaperonin Hsp90 stimulates osteoclastogenesis in vitro and increases bone destruction by invading breast cancer cells. J Bone Miner Res\u20082003; 18: S348."},{"key":"2022061620110284900_B24","unstructured":"Piper PW. The Hsp90 chaperone as a promising drug target. Curr Opin Investig Drugs\u20082001; 2: 1606\u201310."},{"key":"2022061620110284900_B25","doi-asserted-by":"crossref","unstructured":"Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther\u20082002; 2: 3\u201324.","DOI":"10.1517\/14712598.2.1.3"},{"key":"2022061620110284900_B26","doi-asserted-by":"crossref","unstructured":"Soga S, Shiotsu Y, Akinaga S, Sharma SV. Development of radicicol analogues. Curr Cancer Drug Targets\u20082003; 3: 359\u201369.","DOI":"10.2174\/1568009033481859"},{"key":"2022061620110284900_B27","doi-asserted-by":"crossref","unstructured":"Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene\u20082002; 21: 1159\u201366.","DOI":"10.1038\/sj.onc.1205184"},{"key":"2022061620110284900_B28","unstructured":"Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res\u20082003; 9: 4961\u201371."},{"key":"2022061620110284900_B29","unstructured":"Soga S, Neckers LM, Schulte TW, et al. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res\u20081999; 59: 2931\u20138."},{"key":"2022061620110284900_B30","doi-asserted-by":"crossref","unstructured":"Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst\u20081999; 91: 1940\u20139.","DOI":"10.1093\/jnci\/91.22.1940"},{"key":"2022061620110284900_B31","unstructured":"Solit DB, Zheng FF, Drobnjak M, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2\/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res\u20082002; 8: 986\u201393."},{"key":"2022061620110284900_B32","unstructured":"Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res\u20082003; 63: 2139\u201344."},{"key":"2022061620110284900_B33","doi-asserted-by":"crossref","unstructured":"Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets\u20082003; 3: 377\u201383.","DOI":"10.2174\/1568009033481831"},{"key":"2022061620110284900_B34","doi-asserted-by":"crossref","unstructured":"Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther\u20082004; 3: 1021\u201330.","DOI":"10.1158\/1535-7163.1021.3.8"},{"key":"2022061620110284900_B35","doi-asserted-by":"crossref","unstructured":"Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res\u20082001; 16: 1486\u201395.","DOI":"10.1359\/jbmr.2001.16.8.1486"},{"key":"2022061620110284900_B36","doi-asserted-by":"crossref","unstructured":"Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst\u20081990; 82: 1107\u201312.","DOI":"10.1093\/jnci\/82.13.1107"},{"key":"2022061620110284900_B37","unstructured":"Price JT, Tiganis T, Agarwal A, Djakiew D, Thompson EW. Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3\u2032-kinase and phospholipase C-dependent mechanism. Cancer Res\u20081999; 59: 5475\u20138."},{"key":"2022061620110284900_B38","doi-asserted-by":"crossref","unstructured":"Sharp JA, Waltham M, Williams ED, Henderson MA, Thompson EW. Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion in vitro and growth of primary and secondary tumors in nude mice. Clin Exp Metastasis\u20082004; 21: 19\u201329.","DOI":"10.1023\/B:CLIN.0000017167.17065.61"},{"key":"2022061620110284900_B39","doi-asserted-by":"crossref","unstructured":"Stanley ER, Guilbert LJ. Methods for the purification, assay, characterization and target cell binding of a colony stimulating factor (CSF-1). J Immunol Methods\u20081981; 42: 253\u201384.","DOI":"10.1016\/0022-1759(81)90156-3"},{"key":"2022061620110284900_B40","doi-asserted-by":"crossref","unstructured":"Horwood NJ, Elliott J, Martin TJ, Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology\u20081998; 139: 4743\u20136.","DOI":"10.1210\/endo.139.11.6433"},{"key":"2022061620110284900_B41","doi-asserted-by":"crossref","unstructured":"Mirosavljevic D, Quinn JM, Elliott J, Horwood NJ, Martin TJ, Gillespie MT. T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis. J Bone Miner Res\u20082003; 18: 984\u201393.","DOI":"10.1359\/jbmr.2003.18.6.984"},{"key":"2022061620110284900_B42","doi-asserted-by":"crossref","unstructured":"Hodge JM, Kirkland MA, Aitken CJ, et al. Osteoclastic potential of human CFU-GM: biphasic effect of GM-CSF. J Bone Miner Res\u20082004; 19: 190\u20139.","DOI":"10.1359\/JBMR.0301232"},{"key":"2022061620110284900_B43","doi-asserted-by":"crossref","unstructured":"Sims NA, Clement-Lacroix P, Da Ponte F, et al. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest\u20082000; 106: 1095\u2013103.","DOI":"10.1172\/JCI10753"},{"key":"2022061620110284900_B44","doi-asserted-by":"crossref","unstructured":"Price JT, Bonovich MT, Kohn EC. The biochemistry of cancer dissemination. Crit Rev Biochem Mol Biol\u20081997; 32: 175\u2013253.","DOI":"10.3109\/10409239709082573"},{"key":"2022061620110284900_B45","doi-asserted-by":"crossref","unstructured":"Doerr ME, Jones JI. The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells. J Biol Chem\u20081996; 271: 2443\u20137.","DOI":"10.1074\/jbc.271.5.2443"},{"key":"2022061620110284900_B46","doi-asserted-by":"crossref","unstructured":"Nielsen TO, Andrews HN, Cheang M, et al. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Cancer Res\u20082004; 64: 286\u201391.","DOI":"10.1158\/0008-5472.CAN-03-1242"},{"key":"2022061620110284900_B47","doi-asserted-by":"crossref","unstructured":"Burger AM, Fiebig HH, Stinson SF, Sausville EA. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs\u20082004; 15: 377\u201387.","DOI":"10.1097\/00001813-200404000-00011"},{"key":"2022061620110284900_B48","doi-asserted-by":"crossref","unstructured":"Burger AM, Fiebig HH, Stinson SF, Sausville EA. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs\u20082004; 15: 377\u201387.","DOI":"10.1097\/00001813-200404000-00011"},{"key":"2022061620110284900_B49","unstructured":"Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res\u20081995; 55: 3551\u20137."},{"key":"2022061620110284900_B50","doi-asserted-by":"crossref","unstructured":"Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A\u20081999; 96: 3540\u20135.","DOI":"10.1073\/pnas.96.7.3540"},{"key":"2022061620110284900_B51","doi-asserted-by":"crossref","unstructured":"Gu B, Espana L, Mendez O, Torregrosa A, Sierra A. Organ-selective chemoresistance in metastasis from human breast cancer cells: inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus. Carcinogenesis; 2004.","DOI":"10.1093\/carcin\/bgh272"},{"key":"2022061620110284900_B52","unstructured":"Munster PN, Marchion DC, Basso AD, Rosen N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3\u2032-kinase-AKT-dependent pathway. Cancer Res\u20082002; 62: 3132\u20137."},{"key":"2022061620110284900_B53","unstructured":"Bendre MS, Gaddy-Kurten D, Mon-Foote T, et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res\u20082002; 62: 5571\u20139."},{"key":"2022061620110284900_B54","doi-asserted-by":"crossref","unstructured":"Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell\u20082003; 3: 537\u201349.","DOI":"10.1016\/S1535-6108(03)00132-6"},{"key":"2022061620110284900_B55","doi-asserted-by":"crossref","unstructured":"Quinn JM, Itoh K, Udagawa N, et al. Transforming growth factor \u03b2 affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res\u20082001; 16: 1787\u201394.","DOI":"10.1359\/jbmr.2001.16.10.1787"},{"key":"2022061620110284900_B56","doi-asserted-by":"crossref","unstructured":"Lean J, Kirstein B, Urry Z, Chambers T, Fuller K. Thioredoxin-1 mediates osteoclast stimulation by reactive oxygen species. Biochem Biophys Res Commun\u20082004; 321: 845\u201350.","DOI":"10.1016\/j.bbrc.2004.07.035"},{"key":"2022061620110284900_B57","doi-asserted-by":"crossref","unstructured":"Jacquier-Sarlin MR, Polla BS. Dual regulation of heat-shock transcription factor (HSF) activation and DNA-binding activity by H2O2: role of thioredoxin. Biochem J\u20081996; 318: 187\u201393.","DOI":"10.1042\/bj3180187"},{"key":"2022061620110284900_B58","unstructured":"Bagatell R, Paine-Murrieta GD, Taylor CW, et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res\u20082000; 6: 3312\u201318."},{"key":"2022061620110284900_B59","doi-asserted-by":"crossref","unstructured":"Clarke PA, Hostein I, Banerji U, et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene\u20082000; 19: 4125\u201333.","DOI":"10.1038\/sj.onc.1203753"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/11\/4929\/2863451\/4929-4938.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/11\/4929\/2863451\/4929-4938.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T16:36:46Z","timestamp":1655397406000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/65\/11\/4929\/517978\/The-Heat-Shock-Protein-90-Inhibitor-17-Allylamino"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,1]]},"references-count":59,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2005,6,1]]},"published-print":{"date-parts":[[2005,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-04-4458","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,1]]}}}